AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02653898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: 22.5 mg weekly for 12 weeks in the MMP arm; low dose primaquine (15mg) for transmission blocking of P. falciparum or 14 days of primaquine (15mg) in G6PD normal volunteers or 8 weeks of low dose primaquine (45mg) in G6PD-deficient volunteers for radical cure of P. vivax
Study NCT01076764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otamixaban
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion
Study NCT01076764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Otamixaban)
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion
Study NCT01076764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UFH
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion
Study NCT01076764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for UFH)
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion
Study NCT01076764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eptifibatide
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion
Study NCT01076764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Eptifibatide)
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion
Study NCT01639742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New texture round breast implants
Description: Breast implant surgery
Study NCT00321685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00321685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT00321685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT00321685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT00321685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT00321685 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiotherapy
Study NCT00321685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study NCT02820545 — intervention group
Intervention type: OTHER
Intervention: Sociological interview
Description: A sociological interview will be performed with each patient by a sociologist, during their hospital stay
Study NCT02820545 — intervention group
Intervention type: OTHER
Intervention: Self-administrated questionnaire
Description: Self-administrated questionnaire will be performed by patients themselves at the end of hospital stay and one week after they left hospital
Study NCT02952859 — intervention group
Intervention type: OTHER
Intervention: Irreversible electroporation
Study NCT01775293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-absorbable polypropylene mesh
Description: 2 step procedures~* first step is insertion of Non-absorbable polypropylene mesh under the facial skin~* second step is pulling of Non-absorbable polypropylene mesh after 3 weeks of 1 step
Study NCT01550523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGF-1R/AS ODN
Description: Patients will receive approximately 10 to 20 million IGF-1R/AS ODN treated tumor cells, encapsulated in diffusion chambers (maximum of 10), and re-implanted in the patient's abdomen within 24 hours after the surgery for a 24 hour period.
Study NCT01550523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biodiffusion chamber
Description: The biodiffusion chamber is a simple construct comprised of two Lucite rings sealed on either side with a 0.1u mesh filter (Durapore, the Millipore Corporation). Autologous tumor cells pretreated with the IGF-1R AS ODN and resuspended with 2ug of exogenous IGF-1R AS ODN are added to the chamber. Implantation of the chambers (maximum 10 chambers) occurs 24 hours post surgery for 24 hours.
Study NCT03082755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Enacarbil
Description: 1 to 2 GEn tablets (300 milligrams per tablet) will be administered once a day in the evening (about 5pm) for 8 weeks.
Study NCT03082755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 1 to 2 Placebo Oral Tablets will be administered once a day in the evening (about 5pm) for 8 weeks.
Study NCT00002463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOPP Regimen
Description: Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP)
Study NCT00002463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Study NCT00002463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mechlorethamine Hydrochloride
Study NCT00002463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT00002463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT00002463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine Hydrochloride
Study NCT00002463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Study NCT00002463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Study NCT02653898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate + Mefloquine
Description: Weight based; first line agent for P.f malaria infection diagnosed at monthly follow ups, administered on days 1-3 in subjects with malaria recurrence
Study NCT02653898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin (Insecticide treated uniform)
Description: 40% Permethrin IDA kit, applied once to the uniforms for volunteers assigned to ITU arm
Study NCT01375374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: 4-Week Titration Period: start dose Lacosamide (LCM) is 100 mg/day - up-titration of 100 mg/week LCM 8-Week Maintenance Period: dose can change first 4 weeks with 100 mg/week, must remain between 300 mg/day and 600 mg/day. Dose must remain stable last 4 weeks.
Study NCT00368641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extraneal
Description: Periotneal Dialysis
Study NCT01674322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Type=exact number, unit=mg, number=50-140, form=solution, route=oral. Participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
Study NCT01375374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam (LEV) is taken at a stable dose 30 days before study entry and is ≥ 1000 mg/day at the first visit. The LEV dose may not be changed at any time.
Study NCT01810744 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: capillaroscopy
Study NCT01810744 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood pressure measurement
Study NCT03952026 — intervention group
Intervention type: PROCEDURE
Intervention: osteosynthesis of the pelvis
Description: Osteosynthetic Fixation of the pelvic fracture
Study NCT02550925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) Group
Description: A 7-session Acceptance and Commitment Therapy (ACT) group intervention
Study NCT02550925 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Check in with clinical social worker at oncology care site and obtain list of supportive resources
Study NCT05440721 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment A with device Clickotine® (Active intervention)
Description: The intervention regimen around Treatment A is almost entirely user-directed. When a person has a craving, a series of options are available to ease the craving and resist the urge to smoke. The user will also engage with Clickotine® leading up to their quit date to complete a program of 21 Missions, daily activities which help prepare them to quit and keep them off cigarettes. Ideally, the user will open and use Treatment A several times a day.
Study NCT05440721 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Treatment B with smoking education (control)
Description: The Treatment B app is operated by the National Cancer Institute to provide education and support to smokers seeking to quit. The QG regimen is entirely user-directed. When a user has a craving or wants support or education, they can log into the QG app. The QG app also provides lessons relevant for preparing to quit and beginning to quit.
Study NCT00828269 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Comparator: Fine needle aspiration biopsy
Description: Visit 1: Screening Visit 2 (7-14 days from screening): Core needle biopsy and fine needle aspiration biopsy - liver.~Visit 3:(7 days from visit 2): Fine needle aspiration biopsy - liver. Visit 4: (14 days from Visit 3): follow-up visit
Study NCT01955577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo orally everyday
Study NCT00997711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cypher
Description: Sirolimus-eluting stents
Study NCT04486976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cornea/Anterior Segment OCT CASIA2
Description: Cornea/Anterior Segment OCT CASIA2 The Tomey Cornea/Anterior Segment OCT CASIA2 is a non-contact, high resolution tomographic and biomicroscopic device indicated for the in vivo imaging and measurement of ocular structures in the anterior segment, such as corneal thickness. The Tomey Cornea/Anterior Segment OCT CASIA2 is indicated as an aid in the visualization of anterior segment findings.
Study NCT04486976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optovue RTVue XR Avanti
Description: Optovue RTVue XR Avanti The Avanti is an optical coherence tomography system indicated for the in vivo imaging,axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures.
Study NCT01256671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 52 weeks.
Study NCT02419768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The physical exercise program will include 30 sessions of 60 minutes (twice a week). According to the recent guidelines, the program will include a specific work on balance, posture, gait, fitness, dual tasks and stretching.
Study NCT00846508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is available commercially as a sterile lyophilized white power in single-dose amber vials containing 10 mg or 50 mg of cisplatin for administration by IV infusion. Every effort should be made to obtain and record the lot numbers of the batches of cisplatin used. Unopened vials of cisplatin are stable for the shelf-life indicated on the package when stored in accordance with the manufacturers' instructions.
Study NCT00683059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: total dose (mg) = body surface area in m2 x study dose (mg/m2) to be injected into a vein once every 3 weeks over 18 months.
Study NCT05155943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KALPA X™
Description: Before and after a transseptal puncture, the right atrium (RA), left atrial appendage (LAA), and left upper superior pulmonary vein (LUSPV) will be mapped using the KALPA™ system (WS Software ver. 1.0.229-0 Source control ID: 65f1dbf7) in combination with a commercially available catheter. Subjects will then undergo LAAC as per routine clinical care. The entire LAAC procedure will be conducted as customary practice using standard and approved off-the-shelf equipment (body surface electrodes, catheters, etc.) the operator will be blinded to the KALPA™ and KALPA X™ system information.
Study NCT04912310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Argon laser peripheral iridoplasty
Description: Argon laser peripheral iridoplasty was performed in patients with severe acute angle closure glaucoma whose intraocular pressure could not be controlled by medication
Study NCT00778245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefprozil 500mg tablets
Study NCT00778245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefprozil 500mg tablets
Study NCT02820597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClariFix device
Study NCT03118167 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea polyphenols
Description: Tea polyphenols 0.05g, 0.1g, 0.2g (starches filled up to 0.35g), edible capsule
Study NCT03118167 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AOB-w
Description: Water-soluble antioxidant of bamboo leaves 0.35g, edible capsule
Study NCT03118167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Edible starches 0.35g, edible capsule
Study NCT03118167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acrylamide (Potato Chips)
Description: Potato Chips bought from market, corresponding to acrylamide (12.6μg/kg b.w. )
Study NCT03118167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acrylamide (Potato Chips)
Description: Potato Chips bought from market, corresponding to acrylamide (12.6μg/kg b.w. )
Study NCT01863628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Study NCT01863628 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: psychoeducation
Study NCT01636908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50 mg once daily, oral use, 14 days
Study NCT01636908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg, twice daily, oral use, 14 days
Study NCT01636908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg once daily, oral use, 14 days
Study NCT01636908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg once daily, oral use, 14 days
Study NCT01636908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1250 mg once daily, oral use, 14 days
Study NCT01636908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 100 mg once daily, oral use, 14 days
Study NCT01636908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg once daily, oral use, 14 days
Study NCT01636908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 960 mg twice daily, oral use, 15-21 days
Study NCT01636908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tumor biopsy
Study NCT01636908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsy (optional)
Study NCT01229774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: Arcoxia 90 mg once a day in the evening day -1 and 0 and once a day in the morning days 1-7 plus on tablett of placebo every evening
Study NCT01229774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Voltaren Resinat 75mg once a day on day -1 and 0 in the evening; twice a day (in the morning and in the evening) days 1-7
Study NCT02295176 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Armolipid Plus
Study NCT02295176 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01508637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diesel Exhaust
Description: Freshly generated diesel exhaust, diluted to 300 micrograms/cubic meter. Exposures are two hours in duration.
Study NCT01508637 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Filtered Air
Description: Sham exposure, identical to conditions of diesel exhaust exposure, but with only air filtered of particles and volatile organic compound gases
Study NCT01508637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terazosin
Description: 2 mg by mouth, 90 minutes prior to exposure initiation
Study NCT01508637 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Terazosin
Description: 2 mg by mouth, 90 minutes prior to exposure initiation
Study NCT01508637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: capsule, identical in appearance to terazosin capsule, by mouth, 30 minutes prior to exposure initiation
Study NCT01508637 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: capsule, identical in appearance to terazosin capsule, by mouth, 30 minutes prior to exposure initiation
Study NCT01629212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiropramide HCl 100mg
Study NCT01629212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octylonium bromide 20mg
Study NCT01468077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8 mg/kg infusion
Study NCT02701998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth-Enhance Physical Activity Intervention
Study NCT02701998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Intervention
Study NCT02825186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprendol etabonate 0.5%
Description: Steroid eye drops used after strabismus surgery.
Study NCT02825186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1%
Study NCT04398368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given intravesically
Study NCT01012245 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT03008109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TK Inhibitor
Study NCT03437135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Glasgow Hearing Status Inventory questionnaire
Description: This is a questionnaire of the hearing quality presenting eleven questions. This is allows to determine the quality of the hearing status of the patients. It is enough to answer the various questions yes or no.
Study NCT02432963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02432963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Vaccinia Virus Ankara Vaccine Expressing p53
Description: Given SC
Study NCT02432963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT01951404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Study NCT01951404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for allopurinol)
Study NCT03372590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NICU-based rehabilitation bundle
Description: Maternal-driven gestational age-appropriate intervention/activity bundle, including the evidence-based elements of vocal soothing, comforting touch, scent exchange, kangaroo care, and infant massage
Study NCT03372590 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Standard NICU care
Study NCT04721782 — intervention group
Intervention type: OTHER
Intervention: smoking
Description: to assess the effect of smoking of fetal liver circulation with prenatal Doppler Ultrasonography
Study NCT01175759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin test panel
Description: Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)
Study NCT04885348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group (Dental Home Visits + Dental Home Education Leaflets)
Description: No drugs were given in the Intervention. The intervention group received Dental Home Visits consisted of 6 monthly home visits by oral health therapists/dental home visitors where they deliver dental care advice to the parents for durations of approximately 30 minutes until follow-up at two years. Dental Home Education Leaflets (DHELs) and oral health messages were delivered through a personalized approach that avoids direct persuasion. These messages included information on daily tooth brushing with fluoride toothpaste, controlling dietary sugar intake, and the need for regular dental check-ups. The families were also be provided with information about local dental services available in their vicinity and how to access these services.
Study NCT04885348 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (Dental Home Education Leaflets)
Description: Only Dental Home Education Leaflets were provided every six months for 2 years.